Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Schoelch S, Reissfelder C, Weitz J, Schneider M, Wiemann S, Momburg F, Beckhove P (2018)
Publication Type: Journal article
Publication year: 2018
Book Volume: 7
Article Number: e1500671
Journal Issue: 12
DOI: 10.1080/2162402X.2018.1500671
Mutated proteins arising from somatic mutations in tumors are promising targets for cancer immunotherapy. They represent true tumor-specific antigens (TSAs) as they are exclusively expressed in tumors, reduce the risk of autoimmunity and are more likely to overcome tolerance compared to wild-type (wt) sequences. Hence, we designed a panel of long peptides (LPs, 28–35 aa) comprising driver gene mutations in TP35 and KRAS frequently found in gastrointestinal tumors to test their combined immunotherapeutic potential. We found increased numbers of T cells responsive against respective mutated and wt peptides in colorectal cancer patients that carry the tested mutations in their tumors than patients with other mutations. Further, active immunization of HLA(-A2/DR1)-humanized mice with mixes of the same mutated LPs yielded simultaneous, polyvalent CD8+/CD4+ T cell responses against the majority of peptides. Peptide-specific T cells possessed a multifunctional cytokine profile with CD4+ T cells showing a T
APA:
Quandt, J., Schlude, C., Bartoschek, M., Will, R., Cid-Arregui, A., Schoelch, S.,... Beckhove, P. (2018). Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. OncoImmunology, 7(12). https://doi.org/10.1080/2162402X.2018.1500671
MLA:
Quandt, Jasmin, et al. "Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses." OncoImmunology 7.12 (2018).
BibTeX: Download